Completed NA INTERVENTIONAL 2-arm NCT05727813

To Detect Cryoimmunologic Response Induced by Early Breast Cancer Ultrasound-guided Cryoablation (ICE-study)

Early Breast Cancer Ultrasound-guided Visual-ICE Galil Cryoablation; Can Tumor Cell Death Induced by Cryoablation be Detected by Specific Circulating Markers?

Sponsor: University of Roma La Sapienza

Conditions Cancer, Treatment-Related Stage I Breast Cancer Systemic Inflammatory Response Tumor of Breast

Interventions cryoablation

Updated 3 times since 2023 Last updated: Feb 13, 2023 Started: Sep 1, 2022 Primary completion: Jan 16, 2023 Completion: Jan 27, 2023

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This NA trial investigates Cancer, Treatment-Related and Stage I Breast Cancer and is currently completed. University of Roma La Sapienza leads this study, which shows 3 recorded versions since 2022 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

3 versions recorded

Sep 2024 — Present [monthly]

Completed NA
Jul 2024 — Sep 2024 [monthly]

Completed NA
Mar 2023 — Jul 2024 [monthly]

Completed NA

First recorded

Sep 2022

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

University of Roma La Sapienza

Data source: University of Roma La Sapienza

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Roma, Italy